Given the heterogeneity of genomic aberrations for prostate cancer, what are the limitations of PCR-based

Given the heterogeneity of genomic aberrations for prostate cancer, what are the limitations of PCR-based "hot spot" panels for identifying actionable molecular profiles, homozygous deletions and other aberrations?

Given the heterogeneity of genomic aberrations you have described for prostate cancer, what are the limitations of so-called targeted, PCR-based “hot spot” panels for identifying actionable molecular profiles, homozygous deletions and other aberrations in this particular cancer?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Johann De Bono, MD, PhD

Prof. Johann De Bono, MD, PhD

Professor of Experimental Cancer Medicine
Honorary Consultant Medical Oncologist
Royal Marsden Hospital
Head of the Division of Clinical Studies
Institute of Cancer Research
London, UK